Fundamentun LLC boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN – Get Rating) by 1.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,874 shares of the medical research company’s stock after buying an additional 261 shares during the quarter. Fundamentun LLC’s holdings in Amgen were worth $4,957,000 as of its most recent SEC filing.
Several other large investors have also modified their holdings of AMGN. Roundview Capital LLC boosted its holdings in shares of Amgen by 1.3% in the 1st quarter. Roundview Capital LLC now owns 8,383 shares of the medical research company’s stock valued at $2,027,000 after acquiring an additional 107 shares during the last quarter. Merit Financial Group LLC raised its position in shares of Amgen by 39.2% in the first quarter. Merit Financial Group LLC now owns 2,297 shares of the medical research company’s stock valued at $555,000 after buying an additional 647 shares during the last quarter. Ergoteles LLC acquired a new stake in shares of Amgen in the first quarter valued at about $219,000. First Western Trust Bank purchased a new stake in shares of Amgen in the first quarter valued at about $334,000. Finally, Fuller & Thaler Asset Management Inc. grew its holdings in shares of Amgen by 2.1% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 24,688 shares of the medical research company’s stock valued at $5,970,000 after purchasing an additional 513 shares during the period. Institutional investors own 75.53% of the company’s stock.
Analysts Set New Price Targets
Several brokerages have weighed in on AMGN. Credit Suisse Group lowered their target price on shares of Amgen from $240.00 to $220.00 and set an “underperform” rating for the company in a research note on Wednesday, February 1st. StockNews.com started coverage on shares of Amgen in a report on Thursday. They issued a “strong-buy” rating on the stock. Royal Bank of Canada cut their price objective on shares of Amgen from $268.00 to $258.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 1st. Cowen cut their price objective on shares of Amgen from $307.00 to $289.00 and set an “outperform” rating on the stock in a report on Wednesday, February 1st. Finally, SVB Leerink lowered their target price on shares of Amgen from $282.00 to $267.00 and set a “market perform” rating on the stock in a research report on Thursday, February 2nd. Four equities research analysts have rated the stock with a sell rating, three have given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Amgen currently has an average rating of “Hold” and an average price target of $251.44.
Amgen Stock Performance
Amgen (NASDAQ:AMGN – Get Rating) last issued its earnings results on Tuesday, February 7th. The medical research company reported $4.09 EPS for the quarter, topping the consensus estimate of $4.04 by $0.05. The company had revenue of $6.84 billion for the quarter, compared to analyst estimates of $6.77 billion. Amgen had a net margin of 24.89% and a return on equity of 359.47%. The business’s revenue was down .1% on a year-over-year basis. During the same period in the previous year, the firm earned $4.36 EPS. On average, equities analysts expect that Amgen Inc. will post 17.72 EPS for the current year.
Amgen Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, June 8th. Shareholders of record on Thursday, May 18th will be given a dividend of $2.13 per share. The ex-dividend date of this dividend is Wednesday, May 17th. This represents a $8.52 annualized dividend and a dividend yield of 3.71%. Amgen’s payout ratio is currently 70.36%.
Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
- Get a free copy of the StockNews.com research report on Amgen (AMGN)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.